Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Covalent Group Inc (CVGR) an undiscovered CRO -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (70)	11/17/1998 8:20:00 PM
From: vampire	Respond to of 107

does anyone know how long these contracts are for and what margins are like in this business??

To: JanyBlueEyes who wrote (70)	12/17/1998 12:50:00 PM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 107

News - $4 Million Study Covalent Group, Inc. to Conduct $4 Million Clinical Development Study WAYNE, Pa., Dec. 17 /PRNewswire/ -- Covalent Group, Inc. (Nasdaq: CVGR - news) today announced that it has been awarded a $4 million contract from a leading pharmaceutical firm to conduct a major, multi-year, clinical development study. The contract also provides for Covalent to administer and manage an additional $8 million in investigator grants, clinical development fees, and other related expenses. ''This new study, which is in a major therapeutic area, interfaces with our core competency in advanced clinical research and will utilize our integrated electronic centralized patient randomization, drug dispensing and drug tracking system, TeleTrial. This system will cost-effectively accelerate the achievement of the sponsor's clinical research milestones in this study,'' commented Bruce LaMont, Chief Executive Officer. ''Covalent will continue to deliver quality services and innovative solutions to its expanding client base. Our experience and expertise are affording us the opportunity to help ensure the success of our clients' products in the marketplace.'' Covalent provides drug development and health management solutions to pharmaceutical and device manufacturers as well as managed care organizations. To aid its pharmaceutical and managed care customers, Covalent has developed several currently available proprietary products utilizing interactive speech recognition technology including TeleTrial, a clinical trial management system, and Virtual HouseCall, a disease assessment system. This press release contains forward-looking statements. Actual results might differ materially from those projected in the forward-looking statements........ Contact Covalent on-line: cracorp.com